Literature DB >> 23744855

A case series of patients on chemotherapy with dyspnoea and pulmonary infiltrates.

Khalil Ullah1, Aine O'Reilly, Derek G Power, Terence M O'Connor.   

Abstract

Clinicians often assume that patients who develop pulmonary symptoms and radiographic infiltrates while receiving cytotoxic chemotherapy have opportunistic pulmonary infection or chemotherapy-related interstitial lung disease. We describe two cases of rare complications of commonly used chemotherapeutic agents (gemcitabine-induced eosinophilic pneumonia and rituximab-induced hypersensitivity pneumonitis) that vindicate this assumption but a third case of scleroderma-associated interstitial lung disease that became clinically manifest in a patient who was receiving chemotherapy. The latter case highlights the need for vigilance for other causes of interstitial lung disease in patients receiving chemotherapy.

Entities:  

Mesh:

Year:  2013        PMID: 23744855      PMCID: PMC3702826          DOI: 10.1136/bcr-2013-009105

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Gemcitabine-induced acute eosinophilic pneumonia.

Authors:  Young Hak Kim; Michiaki Mishima; Akihiko Yoshizawa
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

2.  Fatal pulmonary toxicity resulting from treatment with gemcitabine.

Authors:  N Pavlakis; D R Bell; M J Millward; J A Levi
Journal:  Cancer       Date:  1997-07-15       Impact factor: 6.860

3.  Gemcitabine-induced pulmonary toxicity.

Authors:  Dow-Chung Chi; Frances Brogan; Ithamar Turenne; Sarah Zelonis; Lawrence Schwartz; Muhammad Wasif Saif
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

Review 4.  Non-infectious pulmonary toxicity of rituximab: a systematic review.

Authors:  Andreas V Hadjinicolaou; Muhammad K Nisar; Helen Parfrey; Edwin R Chilvers; Andrew J K Ostör
Journal:  Rheumatology (Oxford)       Date:  2011-12-07       Impact factor: 7.580

Review 5.  Rituximab-induced lung disease: A systematic literature review.

Authors:  H Lioté; F Lioté; B Séroussi; C Mayaud; J Cadranel
Journal:  Eur Respir J       Date:  2009-07-16       Impact factor: 16.671

6.  Rituximab-induced hypersensitivity pneumonitis.

Authors:  Adriano R Tonelli; Richard Lottenberg; Robert W Allan; P S Sriram
Journal:  Respiration       Date:  2008-10-09       Impact factor: 3.580

7.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

8.  Experience with azathioprine in systemic sclerosis associated with interstitial lung disease.

Authors:  K Dheda; U G Lalloo; B Cassim; G M Mody
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980

9.  Rituximab-induced bronchiolitis obliterans organizing pneumonia.

Authors:  Ahmet B Ergin; Nancy Fong; Hamed A Daw
Journal:  Case Rep Med       Date:  2012-06-19
  9 in total
  1 in total

1.  Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

Authors:  Ibrahim Halil Sahin; Alexander I Geyer; Daniel W Kelly; Eileen Mary O'Reilly
Journal:  Clin Colorectal Cancer       Date:  2015-08-22       Impact factor: 4.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.